Yuanju Zhu

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Idiopathic pulmonary fibrosis (IPF) is a serious and deadly disease for which treatment options are limited. The recent approval of antifibrosis agent nintedanib represents one of the first therapeutic approaches for the treatment of IPF. Here, we report novel indolinone-based multikinase inhibitors that target angiogenesis and fibrosis pathways and may(More)
  • 1